GeoVax Labs, Inc.
Every calculator, already run for GOVX
Open the full toolkit →You have the numbers on GOVX. Get the argument.
A written report on which of these readings actually decide the outcome for GeoVax Labs, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering GOVXOwnership & short interest
Insider Trading Activity for GOVX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02,…
GOVX — frequently asked
Is GOVX a buy right now?
Wall Street's consensus rating on GeoVax Labs, Inc. is Strong Buy across 2 analysts, with a mean price target of $10.00 (+2702% vs. the current $0.36). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare GeoVax Labs, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For GeoVax Labs, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GOVX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on GeoVax Labs, Inc., in minutes. 3 free reports included with every account — no credit card required.